The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
TB constitutes a public health problem at a global level. It’s essential that professionals are well aware of the strategies and solutions for the challenges that TB entails. The End TB Strategy by the WHO calls on governments to commit to the adaptation and implementation of this strategy, relying not only on the health sector, but seeking to comprise a multisectorial effort that’s able to end TB on a global scale.
Following the webinar, participants will be able to:
Panel discussion divided into two parts (of approximately 30 min each):
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: unite4TB.org
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: imi.europa.eu
This communication reflects the author’s view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.”